Jefferies analyst, Brian Abrahams, believes Celgene's (NASDAQ: CELG) REMARC is more likely than not to work, but he sees both ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE